***TASK***
the task is to simplify the input abstract of a biomedical literature

***INPUT***
the input is the abstract of a biomedical literature

***OUTPUT***
the output is the simplified abstract for the input abstract of a biomedical literature

***DOCUMENTATION***

***EXAMPLES***

Input: We included five studies involving 1140 women with asymptomatic bacteriuria. We did not perform meta-analysis; each trial examined different antibiotic regimens and so we were not able to pool results. In a study comparing a single dose of fosfomycin trometamol 3 g with a five-day course of cefuroxime, there was no significant difference in persistent infection (risk ratio (RR) 1.36, 95% confidence interval (CI) 0.24 to 7.75), shift to other antibiotics (RR 0.08, 95% CI 0.00 to 1.45), or in allergy or pruritus (RR 2.73, 95% CI 0.11 to 65.24). A comparison of seven-day courses of 400 mg pivmecillinam versus 500 mg ampicillin, both given four times daily, showed no significant difference in persistent infection at two weeks or recurrent infection, but there was an increase in vomiting (RR 4.57, 95% CI 1.40 to 14.90) and women were more likely to stop treatment early with pivmecillinam (RR 8.82, 95% CI 1.16 to 66.95). When cephalexin 1 g versus Miraxid® (pivmecillinam 200 mg and pivampicillin 250 mg) were given twice-daily for three days, there was no significant difference in persistent or recurrent infection. A one- versus seven-day course of nitrofurantoin resulted in more persistent infection with the shorter course (RR 1.76, 95% CI 1.29 to 2.40), but no significant difference in symptomatic infection at two weeks, nausea, or preterm birth. Comparing cycloserine with sulphadimidine, no significant differences in symptomatic, persistent, or recurrent infections were noted. We cannot draw any definite conclusion on the most effective and safest antibiotic regimen for the initial treatment of asymptomatic bacteriuria in pregnancy. One study showed advantages with a longer course of nitrofurantoin, and another showed better tolerability with ampicillin compared with pivmecillinam; otherwise, there was no significant difference demonstrated between groups treated with different antibiotics. Given this lack of conclusive evidence, it may be useful for clinicians to consider factors such as cost, local availability and side effects in the selection of the best treatment option.
Output:

We included five randomized controlled trials involving 1140 women with urine test results showing asymptomatic bacteriuria. Each of the five studies looked at different antibiotics; thus, we have not pooled the results. Four of the comparisons (fosfomycin versus cefuroxime; pivmecillinam versus ampicillin; cephalexin versus Miraxid® (pivmecillinam 200 mg and pivampicillin 250 mg); and cycloserine versus sulphadimidine) showed no definite advantage of one antibiotic over another for treating infection, side effects, or safety. Ampicillin compared with pivmecillinam resulted in less vomiting and was thus better tolerated by the women in one study. There was however no difference in curing present infection and preventing recurring infection in women who took ampicillin compared with those who took pivmecillinam. In another study comparing a one-day versus a seven-day course of nitrofurantoin, the longer course was better in treating bacteria in urine during pregnancy. Women receiving the shorter course had more persistent infection but no clear difference in symptomatic infection at two weeks, nausea or preterm birth.